Stocks · News reference
Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.654B-$1.695B vs $1.676B Est
Integra Lifesciences (NASDAQ:IART) affirms FY2026 Adj EPS guidance from $2.40-$2.50 to $2.40-$2.50 vs $2.45 analyst estimate. Lowers FY2026 sales outlook from $1.662 billion-$1.702 billion to $1.654 billion-$1.695
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 29, 2026, 10:08 AM
- Checked
- Jul 29, 2026, 10:07 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18
Read original at benzingaIntegra LifeSciences shares are trading lower. The company reported Q2 financial results and lowered its FY26 sales guidance.
Read original at benzinga8-K filing — INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
Filed: 2026-07-29 AccNo: 0000917520-26-000055 Size: 427 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar